自然杀伤细胞介导的针对 SARS-CoV-2 的抗体依赖的细胞细胞毒性在自然感染后比在接种疫苗后更强。
Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination.
机构信息
Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
German Centre for Infection Research, Partner-site Cologne-Bonn, Bonn, Germany.
出版信息
J Infect Dis. 2022 May 16;225(10):1688-1693. doi: 10.1093/infdis/jiac060.
Abstract
We compared the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-specific antibodies to induce natural killer cell-mediated antibody-dependent cellular cytotoxicity (ADCC) in patients with natural infection and vaccinated persons. Analyzing plasma samples from 39 coronavirus disease 2019 (COVID-19) patients and 11 vaccinated individuals, significant induction of ADCC could be observed over a period of more than 3 months in both vaccinated and recovered individuals. Although plasma antibody concentrations were lower in recovered patients, we found antibodies elicited by natural infection induced a significantly stronger ADCC response compared to those induced by vaccination, which may affect protection conferred by vaccination.
摘要
我们比较了严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突特异性抗体在自然感染和接种人群中诱导自然杀伤细胞介导的抗体依赖性细胞细胞毒性（ADCC）的能力。分析了 39 例 2019 年冠状病毒病（COVID-19）患者和 11 名接种者的血浆样本，在接种和康复个体中均能观察到 ADCC 在超过 3 个月的时间内显著诱导。尽管康复患者的血浆抗体浓度较低，但我们发现，与接种疫苗诱导的抗体相比，自然感染诱导的抗体引起的 ADCC 反应要强得多，这可能会影响疫苗接种所提供的保护。
相似文献
1
Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination.自然杀伤细胞介导的针对 SARS-CoV-2 的抗体依赖的细胞细胞毒性在自然感染后比在接种疫苗后更强。
J Infect Dis. 2022 May 16;225(10):1688-1693. doi: 10.1093/infdis/jiac060.
2
SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.SARS-CoV-2 感染引发的抗体依赖细胞介导的细胞毒性（ADCC）反应强于基于 mRNA、载体和灭活病毒的 COVID-19 疫苗。
J Med Virol. 2024 Mar;96(3):e29527. doi: 10.1002/jmv.29527.
3
Antibodies to S2 domain of SARS-CoV-2 spike protein in Moderna mRNA vaccinated subjects sustain antibody-dependent NK cell-mediated cell cytotoxicity against Omicron BA.1.接种 Moderna mRNA 疫苗的受试者中针对 SARS-CoV-2 刺突蛋白 S2 结构域的抗体可维持针对奥密克戎 BA.1 的抗体依赖的 NK 细胞介导的细胞细胞毒性。
Front Immunol. 2023 Nov 21;14:1266829. doi: 10.3389/fimmu.2023.1266829. eCollection 2023.
4
Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.自然杀伤细胞介导的 ADCC 在 SARS-CoV-2 感染个体和疫苗接种者中的作用。
Eur J Immunol. 2022 Aug;52(8):1297-1307. doi: 10.1002/eji.202149470. Epub 2022 Apr 22.
5
The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.功能性抗体依赖的细胞介导的细胞毒性（ADCC）针对 SARS-CoV-2 刺突蛋白的发展和动力学。
Virology. 2021 Jul;559:1-9. doi: 10.1016/j.virol.2021.03.009. Epub 2021 Mar 19.
6
Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.Siglec-9 抑制针对 SARS-CoV-2 的抗体依赖的自然杀伤细胞细胞毒性。
mBio. 2023 Feb 28;14(1):e0339322. doi: 10.1128/mbio.03393-22. Epub 2023 Feb 2.
7
Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.新冠病毒感染康复者血浆中存在针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗体依赖性细胞毒性（ADCC）
PLoS One. 2021 Mar 4;16(3):e0247640. doi: 10.1371/journal.pone.0247640. eCollection 2021.
8
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.比较 BNT162b2 mRNA 疫苗接种者的恢复期和未接种者的 SARS-CoV-2 抗刺突蛋白 RBD IgG 和中和抗体与 COVID-19 患者的动力学。
BMC Med. 2021 Aug 23;19(1):208. doi: 10.1186/s12916-021-02090-6.
9
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.新型冠状病毒刺突蛋白受体结合域线性表位在 COVID-19 mRNA 疫苗接种者中的高分辨率线性表位作图。
Microbiol Spectr. 2021 Dec 22;9(3):e0096521. doi: 10.1128/Spectrum.00965-21. Epub 2021 Nov 10.
10
Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein.基于细胞的报告基因检测法用于测量针对 SARS-CoV-2 刺突蛋白的抗体介导的细胞毒性和吞噬作用。
J Virol Methods. 2022 Sep;307:114564. doi: 10.1016/j.jviromet.2022.114564. Epub 2022 Jun 6.
引用本文的文献
1
Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.莫桑比克队列中接种1剂或2剂BBIBP-CorV疫苗后的混合免疫
Clin Infect Dis. 2025 Jul 22;80(Supplement_1):S57-S65. doi: 10.1093/cid/ciaf095.
2
A longitudinal assessment of the antibody response to SARS-CoV-2 infection in the New Mexican population.对新墨西哥州人群中SARS-CoV-2感染抗体反应的纵向评估。
PLoS One. 2025 Jul 8;20(7):e0327698. doi: 10.1371/journal.pone.0327698. eCollection 2025.
3
Protective Potential and Functional Role of Antibodies Against SARS-CoV-2 Nucleocapsid Protein.抗SARS-CoV-2核衣壳蛋白抗体的保护潜力及功能作用
Antibodies (Basel). 2025 May 28;14(2):45. doi: 10.3390/antib14020045.
4
High-affinity CD16A polymorphism associated with reduced risk ofsevere COVID-19.与严重新型冠状病毒肺炎风险降低相关的高亲和力CD16A基因多态性
JCI Insight. 2025 May 22;10(13). doi: 10.1172/jci.insight.191314. eCollection 2025 Jul 8.
5
NK cells modulate in vivo control of SARS-CoV-2 replication and suppression of lung damage.自然杀伤细胞调节体内对 SARS-CoV-2 复制的控制和肺损伤的抑制。
PLoS Pathog. 2024 Aug 12;20(8):e1012439. doi: 10.1371/journal.ppat.1012439. eCollection 2024 Aug.
6
Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.异源mRNA/MVA递送三聚体RBD作为针对SARS-CoV-2的有效疫苗接种方案：COVARNA联盟
Emerg Microbes Infect. 2024 Dec;13(1):2387906. doi: 10.1080/22221751.2024.2387906. Epub 2024 Aug 8.
7
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques.在恒河猴中，Spike Ferritin Nanoparticle 疫苗接种可引发多样化的中和抗体。
Nat Commun. 2024 Jan 3;15(1):200. doi: 10.1038/s41467-023-44265-0.
8
Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1.在 HIV-1 感染者中，SARS-CoV-2 感染和接种疫苗期间的自然杀伤细胞反应。
Sci Rep. 2023 Nov 3;13(1):18994. doi: 10.1038/s41598-023-45412-9.
9
Deficient Immune Response following SARS-CoV-2 Vaccination in Patients with Hepatobiliary Carcinoma: A Forgotten, Vulnerable Group of Patients.SARS-CoV-2疫苗接种后肝胆癌患者的免疫反应不足：一群被遗忘的脆弱患者。
Liver Cancer. 2023 May 10;12(4):339-355. doi: 10.1159/000529608. eCollection 2023 Sep.
10
Defining the role of natural killer cells in COVID-19.定义自然杀伤细胞在 COVID-19 中的作用。
Nat Immunol. 2023 Oct;24(10):1628-1638. doi: 10.1038/s41590-023-01560-8. Epub 2023 Jul 17.
Zotero 插件